175 related articles for article (PubMed ID: 37864646)
1. Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma.
Strowd R; Ellingson B; Raymond C; Yao J; Wen PY; Ahluwalia M; Piotrowski A; Desai A; Clarke JL; Lieberman FS; Desideri S; Nabors LB; Ye X; Grossman S
J Neurooncol; 2023 Oct; 165(1):101-112. PubMed ID: 37864646
[TBL] [Abstract][Full Text] [Related]
2. pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma.
Yao J; Tan CHP; Schlossman J; Chakhoyan A; Raymond C; Pope WB; Salamon N; Lai A; Ji M; Nghiemphu PL; Liau LM; Cloughesy TF; Ellingson BM
J Neurooncol; 2019 May; 142(3):587-595. PubMed ID: 30806888
[TBL] [Abstract][Full Text] [Related]
3. Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor.
Renfrow JJ; Soike MH; West JL; Ramkissoon SH; Metheny-Barlow L; Mott RT; Kittel CA; D'Agostino RB; Tatter SB; Laxton AW; Frenkel MB; Hawkins GA; Herpai D; Sanders S; Sarkaria JN; Lesser GJ; Debinski W; Strowd RE
Sci Rep; 2020 Sep; 10(1):15195. PubMed ID: 32938997
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of MEDI-575, an anti-platelet-derived growth factor-α antibody, in patients with recurrent glioblastoma.
Phuphanich S; Raizer J; Chamberlain M; Canelos P; Narwal R; Hong S; Miday R; Nade M; Laubscher K
J Neurooncol; 2017 Jan; 131(1):185-191. PubMed ID: 27844311
[TBL] [Abstract][Full Text] [Related]
5. Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.
Ellingson BM; Aftab DT; Schwab GM; Hessel C; Harris RJ; Woodworth DC; Leu K; Chakhoyan A; Raymond C; Drappatz J; de Groot J; Prados MD; Reardon DA; Schiff D; Chamberlain M; Mikkelsen T; Desjardins A; Holland J; Ping J; Weitzman R; Wen PY; Cloughesy TF
Neuro Oncol; 2018 Sep; 20(10):1411-1418. PubMed ID: 29660005
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
[TBL] [Abstract][Full Text] [Related]
7. Outcomes and prognostic stratification of patients with recurrent glioblastoma treated with salvage stereotactic radiosurgery.
Sharma M; Schroeder JL; Elson P; Meola A; Barnett GH; Vogelbaum MA; Suh JH; Chao ST; Mohammadi AM; Stevens GHJ; Murphy ES; Angelov L
J Neurosurg; 2018 Oct; 131(2):489-499. PubMed ID: 30485180
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma.
Kaley TJ; Panageas KS; Mellinghoff IK; Nolan C; Gavrilovic IT; DeAngelis LM; Abrey LE; Holland EC; Lassman AB
J Neurooncol; 2019 Sep; 144(2):403-407. PubMed ID: 31325145
[TBL] [Abstract][Full Text] [Related]
9. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
Huang J; Chaudhary R; Cohen AL; Fink K; Goldlust S; Boockvar J; Chinnaiyan P; Wan L; Marcus S; Campian JL
J Neurooncol; 2019 May; 142(3):537-544. PubMed ID: 30771200
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma.
Kalpathy-Cramer J; Chandra V; Da X; Ou Y; Emblem KE; Muzikansky A; Cai X; Douw L; Evans JG; Dietrich J; Chi AS; Wen PY; Stufflebeam S; Rosen B; Duda DG; Jain RK; Batchelor TT; Gerstner ER
J Neurooncol; 2017 Feb; 131(3):603-610. PubMed ID: 27853960
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of Dovitinib in recurrent glioblastoma.
Sharma M; Schilero C; Peereboom DM; Hobbs BP; Elson P; Stevens GHJ; McCrae K; Nixon AB; Ahluwalia MS
J Neurooncol; 2019 Sep; 144(2):359-368. PubMed ID: 31292802
[TBL] [Abstract][Full Text] [Related]
12. Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma.
Nayak L; Molinaro AM; Peters K; Clarke JL; Jordan JT; de Groot J; Nghiemphu L; Kaley T; Colman H; McCluskey C; Gaffey S; Smith TR; Cote DJ; Severgnini M; Yearley JH; Zhao Q; Blumenschein WM; Duda DG; Muzikansky A; Jain RK; Wen PY; Reardon DA
Clin Cancer Res; 2021 Feb; 27(4):1048-1057. PubMed ID: 33199490
[TBL] [Abstract][Full Text] [Related]
13. Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.
Courtney KD; Infante JR; Lam ET; Figlin RA; Rini BI; Brugarolas J; Zojwalla NJ; Lowe AM; Wang K; Wallace EM; Josey JA; Choueiri TK
J Clin Oncol; 2018 Mar; 36(9):867-874. PubMed ID: 29257710
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.
Field KM; Simes J; Nowak AK; Cher L; Wheeler H; Hovey EJ; Brown CS; Barnes EH; Sawkins K; Livingstone A; Freilich R; Phal PM; Fitt G; ; Rosenthal MA
Neuro Oncol; 2015 Nov; 17(11):1504-13. PubMed ID: 26130744
[TBL] [Abstract][Full Text] [Related]
15. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
Heiland DH; Masalha W; Franco P; Machein MR; Weyerbrock A
J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518
[TBL] [Abstract][Full Text] [Related]
16. Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.
McBain C; Lawrie TA; Rogozińska E; Kernohan A; Robinson T; Jefferies S
Cochrane Database Syst Rev; 2021 May; 5(1):CD013579. PubMed ID: 34559423
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R
Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371
[TBL] [Abstract][Full Text] [Related]
18. Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma.
Ghiaseddin A; Reardon D; Massey W; Mannerino A; Lipp ES; Herndon JE; McSherry F; Desjardins A; Randazzo D; Friedman HS; Peters KB
Oncologist; 2018 Feb; 23(2):157-e21. PubMed ID: 29133513
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
[TBL] [Abstract][Full Text] [Related]
20. Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial.
Oehler C; Frei K; Rushing EJ; McSheehy PM; Weber D; Allegrini PR; Weniger D; Lütolf UM; Knuth A; Yonekawa Y; Barath K; Broggini-Tenzer A; Pruschy M; Hofer S
Oncology; 2012; 83(1):1-9. PubMed ID: 22688083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]